Abstract: A cell plan operation, a Routine and a base station are disclosed wherein user entities are allocated to at least two carriers (C1; C2) in at least one cell (A; B) of a system (node B), the first carrier (C1) having at least a first channel (DPCH), the second carrier (C2) having at least a second channel (DPCH), the at least two carriers not causing interference to one another, wherein user entities (UE) may be selectively assigned to either first channel and/or the second channel. Information is gathered on respective measures relating to the noise enduring capability (MAX ROT(UEn)) of respective prevalent users within the at least one cell. Prevalent user entities are ordered according to their respective noise enduring capabilities (MAX_ROT(UEn)_UE). User entities with low noise enduring capabilities are allocated to a channel on the first carrier (C1), while user entities with high noise enduring capabilities (MAX_ROT(UEn)) are allocated to a channel on the second carrier (C2).

Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.

Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.

Abstract: The invention provides a method for generating a polynucleotide sequence or population of sequences from parent single stranded polynucleotide sequences encoding one or more protein motifs, comprising the steps of a) providing single stranded DNA constituting plus and minus strands of parent polynucleotide sequences; b) digesting the single stranded polynucleotide sequences with a nuclease other than DNase I to generate populations of single stranded fragments; c) contacting said fragments generated from the plus strands with fragments generated from the minus strands and optionally, adding primer sequences that anneal to the 3? and 5? ends of at least one of the parent polynucleotides under annealing conditions; d) amplifying the fragments that anneal to each other to generate at least one polynucleotide sequence encoding one or more protein motifs having altered characteristics as compared to the one or more protein motifs encoded by said parent polynucleotides.

Abstract: A method for in vitro molecular evolution of protein function The invention provides a method for generating a polynucleotide sequence or population of sequences from parent single-stranded polynucleotide sequences encoding one or more protein motifs, comprising the steps of (a) providing a first population of single-stranded polynucleotide molecules and a second population of single-stranded polynucleotide molecules, the first and second populations together constituting plus and minus strands of parent polynucleotide sequences, (b) carrying out a reaction for digesting the first and second populations of single-stranded polynucleotide molecules with an exonuclease to generate corresponding populations of single-stranded polynucleotide fragments, (c) contacting said fragments generated from the plus strands with fragments generated from the minus strands and optionally, adding primer sequences that anneal to the 3? and 5?ends of at least one of the parent polynucleotides under annealing conditions, and (d) a

Abstract: The invention refers to an arrangement and a method for minimizing intracell and/or intercell interference for a data transmission system comprising a scheduler (2). A first base station (BS) receives information from user equipments (UE1-UE4) in a first cell (1), by means of a first antenna system (Rx, Tx). The scheduler (2) identifies the position of each user is and allots a first time slot (TS1) to at least one user equipment (UE1) in a first cell segment (CS1) in the first cell (1). The scheduler (2) also allots the first time slot to at least one user (UE3) equipment in a second cell segment (CS2) in the first cell (1). The antenna system (Rx, Tx) then sends information from the base station (BS) simultaneously to all user equipments (UE1, UE3) allotted to the first time slot.

Abstract: The present invention relates to a method and arrangement for downlink power adjustment in a base station (210, 310, 610) comprising at least two similar hardware units: a first unit (231, 316a, 616a) and a second unit (232, 316b, 616b), in a communications network when moving a resource from said first unit to said second unit. The method comprises configuring said resource, providing a sample of a power level, transferring said power sample from said first unit to said second unit, and controlling the power level on the second unit towards a power value provided as a power level with turned off output power on said second unit.

Abstract: A transmitting unit comprising a first unit (CM_SCHDR) receiving scheduled first data (DATA2, DATA3) for transmission on at least a first channel, a power control unit (PWR_CTRL) for the first channel responsive to a respective closed loop power regulation signal (TCP_CMD), under which at least the transmit power rate of change is limited to a predetermined value per time unit, a packet data scheduler (HS_SCHDR) scheduling second data packets (DATA1), such as HSPDA data, for transmission on at least a second channel at an actual power level (P_H(t)), and a power amplifier (POWER_AMP) amplifying and outputting the scheduled first and second data, whereby the outputted first and second channels are subject to interference from one another, is shown.

Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.

Abstract: Transmission unit comprising a first unit (CM_SCHDR) receiving scheduled first data (DATA2, DATA3) for transmission on at least a first channel, a power control unit (PWR_CTRL) for the first channel responsive to a respective closed loop power regula-tion signal (TCP_CMD), under which at least the transmit power rate of change is limited to a predetermined value per time unit, a packet data scheduler (HS_SCHDR) schedul-ing second data packets (DATA1), such as HSDPA data. A permitted power (P_PERM(t)) is defined as the maximum value of either the actual power of a previous instance (P_HS(t?1)) added with the predetermined value (d) or the determined possible power (P_POS(t)). Moreover, an available power is resolved. According to one aspect, the scheduling is performed within these limits. According to a further aspect the power level of the signaling and control channel (HS-SCCH) is further regulated during a transmission interval taking account of shared packet data channel (HS-PDSCH) power level.

Abstract: A single isolated antibody or antibody fragment thereof binds to multiple variant sequences within an epitope of HIV-1 Tat protein displayed in multiple strains and subtypes of HIV-1. This “pan-epitope” antibody is useful in therapeutic and prophylactic compositions and treatments of HIV-1 infection, regardless of strain. This pan-epitope antibody is useful in assays for the detection of levels of HIV-1 based on a measurement of the amount of Tat protein in a biological sample.

Abstract: A method for in vitro molecular evolution of protein function The invention provides a method for generating a polynucleotide sequence or population of sequences from parent single-stranded polynucleotide sequences encoding one or more protein motifs, comprising the steps of (a) providing a first population of single-stranded polynucleotide molecules and a second population of single-stranded polynucleotide molecules, the first and second populations together constituting plus and minus strands of parent polynucleotide sequences, (b) carrying out a reaction for digesting the first and second populations of single-stranded polynucleotide molecules with an exonuclease to generate corresponding populations of single-stranded polynucleotide fragments, (c) contacting said fragments generated from the plus strands with fragments generated from the minus strands and optionally, adding primer sequences that anneal to the 3? and 5?ends of at least one of the parent polynucleotides under annealing conditions, and (d) a

Abstract: The invention provides a method for generating a polynucleotide sequence or population of sequences from parent single stranded polynucleotide sequences encoding one or more protein motifs, comprising the steps of a) providing single stranded DNA constituting plus and minus strands of parent polynucleotide sequences; b) digesting the single stranded polynucleotide sequences with a nuclease other than DNase I to generate populations of single stranded fragments; c) contacting said fragments generated from the plus strands with fragments generated from the minus strands and optionally, adding primer sequences that anneal to the 3? and 5? ends of at least one of the parent polynucleotides under annealing conditions; d) amplifying the fragments that anneal to each other to generate at least one polynucleotide sequence encoding one or more protein motifs having altered characteristics as compared to the one or more protein motifs encoded by said parent polynucleotides.

Abstract: The invention provides a method for generating a polynucleotide sequence or population of sequences from parent single stranded polynucleotide sequences encoding one or more protein motifs, comprising the steps of (a) providing single stranded DNA constituting plus and minus strands of parent polynucleotide sequences; (b) digesting the single stranded polynucleotide sequences with a nuclease other than DNase I to generate populations of single stranded fragments; (c) contacting said fragments generated from the plus strands with fragments generated from the minus strands and optionally, adding primer sequences that anneal to the 3? and 5? ends of at least one of the parent polynucleotides under annealing conditions; (d) amplifying the fragments that anneal to each other to generate at least one polynucleotide sequence encoding one or more protein motifs having altered characteristics as compared to the one or more protein motifs encoded by said parent polynucleotides.

Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.

Abstract: The invention relates to methods of making arrays of anti-ligands for use in the analysis of ligands. Preferred ligands are proteins and preferred anti-ligands are antibodies, or antigen-binding variants or derivatives thereof. The microarrays of the invention provide a convenient means for analysing differential protein expression in cells.

Abstract: The present invention provides a method for producing a polynucleotide sequence encoding an antibody variable domain, the variable domain comprising complementarity-determining regions (CDRs) located within a selected framework (the ‘master framework’), the method comprising the steps of (a) providing at least one nucleic acid molecule encoding one or more CDRs and associated framework regions (the ‘original framework’), (b) amplifying at least one CDR-encoding portion of the nucleic acid molecule(s) of step (a) using one or more pairs of oligonucleotides as amplification primers and (c) assembling a polynucleotide sequence encoding an antibody variable domain by combining the amplified CDR-encoding nucleotide sequences produced in step (b) with nucleotide sequences encoding said master framework, wherein the oligonucleotide primers of step (b) comprise nucleotide sequences which differ from the corresponding nucleotide sequences encoding said master framework.

Abstract: The invention provides a method for generating a polynucleotide sequence or population of sequences from parent single stranded polynucleotide sequences encoding one or more protein motifs, comprising the steps of

Abstract: Method and device for casting cast iron including a metal chill mold (100) having outer walls (206, 208, 210) and inner walls (212, 213, 220). The inner walls are in contact with a mold (300). The device further includes pressurizing means (400) for applying a variable pressure on the outer walls (206, 208, 210) of the chill mold, in order to control changes in volume of molten material enclosed by the chill mold, and chill mold cooling means (500) for variable cooling of the inner walls (212, 213, 220) of said chill mold.

Abstract: The invention relates to methods of making arrays of anti-ligands for use in the analysis of ligands. Preferred ligands are proteins and preferred anti-ligands are antibodies, or antigen-binding variants or derivatives thereof. The microarrays of the invention provide a convenient means for analysing differential protein expression in cells.